TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23731081

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Four-port laparoscopic cholecystectomy
Number of subjects: 60
Study: 20575290

Group type: EXPERIMENTAL
Intervention: Ulinastatin (10,000 U/kg after skin incision, 5,000 U/kg after operation on days 1, 2, 3)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 40
Study: 19865633

Group type: EXPERIMENTAL
Intervention: Platform-switched implants
Number of subjects: 45

Group type: COMPARATOR
Intervention: External-hexagon implants
Number of subjects: 45
Study: 15733514

Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Salbutamol from MDI
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Local anaesthetic cream applied to face
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Local anaesthetic cream applied to back of hand
Number of subjects: 24
Study: 12874415

Group type: EXPERIMENTAL
Intervention: 12-month treatment with IV anti-T-lymphocyte immunoglobulin followed by oral methotrexate 7.5 mg/week (ATG group)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 12-month treatment with oral methotrexate 7.5 mg/week alone (MTX group)
Number of subjects: 11
Study: 10369711

Group type: EXPERIMENTAL
Intervention: Octreotide 100 microg, subcutaneous injection three times daily for seven days
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Octreotide 200 microg, subcutaneous injection three times daily for seven days
Number of subjects: 302

Group type: COMPARATOR
Intervention: Placebo, subcutaneous injection three times daily for seven days
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: All treatment groups (Octreotide and Placebo)
Number of subjects: 302
Study: 8899313

Group type: EXPERIMENTAL
Intervention: Ukrain monotherapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU) and X‐ray therapy
Number of subjects: 96
Study: 1893902

Group type: EXPERIMENTAL
Intervention: Cross-country skiing training for 9-10 weeks, 40-min sessions, 3 times a week at 75%-85% VO2max
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Running training for 9-10 weeks, 40-min sessions, 3 times a week at 75%-85% VO2max
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Combined exercise groups (skiing and running)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: All groups (skiing, running, control)
Number of subjects: 66
Study: 6407749

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) for 4 malnourished children for 28 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition plus enteral nutrition for 4 malnourished children for 28 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Comprehensive enteral nutrition program for 7 nourished children
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) for 2 nourished children
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nourished children at diagnosis
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Malnourished children at diagnosis
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nourished or becoming renourished during the first 21 days of therapy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Becoming malnourished or remaining malnourished during the first 21 days of therapy
Number of subjects: 18
Study: 30914102

Group type: EXPERIMENTAL
Intervention: Sodium acetate Ringer solution infusion (group A: 4 mL·kg‐1·h‐1, group B: increased by 50%, group C: increased by 100%) for 30 minutes
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sodium acetate Ringer solution infusion (group B)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sodium acetate Ringer solution infusion (group A)
Number of subjects: 26
Study: 28012569

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (MPA) 80 mg, 2 mL
Number of subjects: 100

Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TA) 80 mg, 2 mL
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (MPA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both MPA and TA
Number of subjects: 100
Study: 25875954

Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy with intrapericardial tube (study group)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (no pericardial space intervention)
Number of subjects: 210
Study: 25161294

Group type: EXPERIMENTAL
Intervention: cilostazol
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 22393902

Group type: EXPERIMENTAL
Intervention: 4 mmHg stepwise balloon distensions
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Colonic compliance
Number of subjects: 60
Study: 19384218

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (100 mg/kg bolus; 20 mg.kg.hr infusion until 4 hours after cardiopulmonary bypass)
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 177

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study: 17906573

Group type: EXPERIMENTAL
Intervention: ProDisc at 1 level
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: ProDisc at 2 levels
Number of subjects: 59
Study: 15121491

Group type: EXPERIMENTAL
Intervention: Spironolactone (mean dose 32 +/- 16 mg)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 93
Study: 11299253

Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 40
Study: 10374446

Group type: EXPERIMENTAL
Intervention: Bronchofiberscope and catheter intervention with ofloxacin and amikacin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 48
Study: 7949085

Group type: EXPERIMENTAL
Intervention: HHV‐6 isolation from bone marrow samples of patients with idiopathic BM suppression (IBMS)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: HHV‐6 isolation from bone marrow samples of patients with diagnosed BM suppression (DBMS)
Number of subjects: 15

Group type: COMPARATOR
Intervention: HHV‐6 isolation from control BM samples from another population of BMT patients
Number of subjects: 15
Study: 3128767

Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tobramycin and Azlocillin (Control)
Number of subjects: 30
Study: 31891288

Group type: COMPARATOR
Intervention: HLA‐DRB1*13 allele
Number of subjects: 165

Group type: COMPARATOR
Intervention: HLA‐DRB1*09 allele
Number of subjects: 165
Study: 30638544

Group type: EXPERIMENTAL
Intervention: Liothyronine (T3) therapy (maximum dosage 15 mcg/m2/die)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Liothyronine (T3) therapy (T3-treated group)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Comparison between T3-treated and untreated groups
Number of subjects: 37
Study: 27666144

Group type: EXPERIMENTAL
Intervention: Non-reference radiologists' grading of VUR
Number of subjects: 602

Group type: COMPARATOR
Intervention: Reference radiologists' adjudicated grading of VUR
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Non-reference radiologists' grading of VUR compared to reference radiologists' adjudicated grade
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Agreement on VUR grade when participant was the unit of analysis
Number of subjects: 602
Study: 27173586

Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 25198275

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion for less than 12 hours
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion for 12-18 hours
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion for greater than 18 hours
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion (all durations)
Number of subjects: 933
Study: 22792882

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 89
Study: 19165617

Group type: EXPERIMENTAL
Intervention: Totally tubeless PCNL (Group 1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard PCNL with 14F malecot nephrostomy catheter (Group 2)
Number of subjects: 90
Study: 17317371

Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg
Number of subjects: 306

Group type: COMPARATOR
Intervention: atorvastatin 80 mg
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg (in subjects with low HDL cholesterol)
Number of subjects: 306

Group type: COMPARATOR
Intervention: atorvastatin 80 mg (in subjects with low HDL cholesterol)
Number of subjects: 306
Study: 15063607

Group type: EXPERIMENTAL
Intervention: rosuvastatin 5 mg
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 216

Group type: COMPARATOR
Intervention: placebo/rosuvastatin
Number of subjects: 216

Group type: COMPARATOR
Intervention: placebo/fenofibrate
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/fenofibrate
Number of subjects: 216
Study: 11166974

Group type: EXPERIMENTAL
Intervention: Methadone (0 h)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Methadone (3 h)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cold pressor test (Methadone patients at 0 h)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cold pressor test (Methadone patients at 3 h)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (Methadone patients at 0 h)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (Methadone patients at 3 h)
Number of subjects: 32
Study: 9442174

Group type: EXPERIMENTAL
Intervention: Oxytocin and amniotomy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Amniotomy only
Number of subjects: 61

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both intervention groups (oxytocin and amniotomy, amniotomy only)
Number of subjects: 61
Study: 8560369

Group type: EXPERIMENTAL
Intervention: Free screening test provided to the experimental group.
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no free screening test provided).
Number of subjects: 81
Study: 2133472

Group type: EXPERIMENTAL
Intervention: Treatment by a dentist
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Craniomandibular disorder treatment group
Number of subjects: 55

Group type: COMPARATOR
Intervention: Treatment by a neurologist
Number of subjects: 55
Study: 330766

Group type: EXPERIMENTAL
Intervention: 0.1% triamcinolone acetonide (TA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone (HC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0
Study: 28384065

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg every 21 days)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Interferon alfa-2b (5 million units three times per week)
Number of subjects: 427
Study: 25554623

Group type: EXPERIMENTAL
Intervention: D-serine (DSR) 2.1 g orally administered
Number of subjects: 35
Study: 24283280

Group type: EXPERIMENTAL
Intervention: NaF-silica dentifrice (Aquafresh Advanced, 1,150 ppm F(-))
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control dentifrice (250 ppm F(-), same base)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Brushing duration (45, 60, 120, or 180 seconds)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dentifrice quantity (0.5 g vs 1.5 g)
Number of subjects: 42
Study: 21954166

Group type: EXPERIMENTAL
Intervention: Yale Physical Activity Survey (YPAS)
Number of subjects: 310
Study: 19523207

Group type: EXPERIMENTAL
Intervention: Lokomat robotic gait orthosis
Number of subjects: 16

Group type: COMPARATOR
Intervention: Manual-assisted body-weight supported treadmill training (BWSTT)
Number of subjects: 16
Study: 17143175

Group type: EXPERIMENTAL
Intervention: AngQb (400 microg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: AngQb (100 microg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ramipril (1 mg/kg per day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: VLP alone
Number of subjects: 12
Study: 15108979

Group type: EXPERIMENTAL
Intervention: Amino acid infusion at 4 kJ x kg(‐1) x h(‐1) for 2.5 h combined with skin‐surface warming
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Amino acid infusion combined with cutaneous cooling
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline infusion combined with skin‐surface warming
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline infusion combined with cutaneous cooling
Number of subjects: 9
Study: 11451721

Group type: EXPERIMENTAL
Intervention: DASH diet (increased fruit, vegetables, and low-fat dairy; reduced saturated fat, total fat, and cholesterol)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Fruit and vegetable diet
Number of subjects: 436
Study: 9738579

Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy (CHART)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 356
Study: 8031555

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg, 20 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Perindopril (4 mg, 8 mg)
Number of subjects: 20
Study: 2029111

Group type: EXPERIMENTAL
Intervention: Methotrexate (7.5 mg weekly, increased to 15 mg after 8 weeks if clinically effective)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Azathioprine (100 mg daily, increased to 150 mg after 8 weeks if clinically effective)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 64

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 64
Study: 318908

Group type: EXPERIMENTAL
Intervention: Butorphanol 2.0 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Butorphanol 0.5 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Butorphanol 1.0 mg
Number of subjects: 125

Group type: COMPARATOR
Intervention: Meperidine 20 mg
Number of subjects: 125

Group type: COMPARATOR
Intervention: Meperidine 40 mg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Butorphanol 0.5 mg and 1.0 mg
Number of subjects: 125

Group type: COMPARATOR
Intervention: Meperidine group
Number of subjects: 125
Study: 31094614

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Multivitamin placebo
Number of subjects: 60
Study: 28553076

Group type: EXPERIMENTAL
Intervention: 2.5 μg/kg palonosetron
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 7.5 μg/kg palonosetron
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 2.5 μg/kg palonosetron and 15 μg/kg droperidol
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 129
Study: 25651245

Group type: EXPERIMENTAL
Intervention: Oral tenofovir disoproxil fumarate (TDF)
Number of subjects: 5029

Group type: EXPERIMENTAL
Intervention: Oral tenofovir-emtricitabine (TDF-FTC)
Number of subjects: 5029

Group type: EXPERIMENTAL
Intervention: 1% tenofovir (TFV) vaginal gel
Number of subjects: 5029

Group type: COMPARATOR
Intervention: Oral TDF-FTC
Number of subjects: 5029
Study: 23905525

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome
Number of subjects: 4619

Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 4619

Group type: COMPARATOR
Intervention: Adjustment for BMI
Number of subjects: 4619

Group type: COMPARATOR
Intervention: Adjustment for metabolic syndrome
Number of subjects: 4619

Group type: EXPERIMENTAL
Intervention: Stepwise model
Number of subjects: 4619
Study: 16466655

Group type: EXPERIMENTAL
Intervention: 7 mg nicotine patch
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 12719051

Group type: EXPERIMENTAL
Intervention: Preoperative and intraoperative active warming
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intraoperative warming only
Number of subjects: 30

Group type: COMPARATOR
Intervention: No special precautions (control group)
Number of subjects: 30
Study: 10028980

Group type: EXPERIMENTAL
Intervention: Home-based mass antibiotic treatment (azithromycin, ciprofloxacin, metronidazole)
Number of subjects: 12726

Group type: COMPARATOR
Intervention: Control group (vitamins/anthelmintic drug)
Number of subjects: 12726
Study: 8897864

Group type: EXPERIMENTAL
Intervention: L-glutamine (800 mumol.kg-1.h-1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Glycine (isonitrogenous infusion)
Number of subjects: 7
Study: 1324895

Group type: COMPARATOR
Intervention: RT (45 Gy/15 fractions/3 weeks)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: RT and daily low dose of cDDP (6 mg/m2)
Number of subjects: 173
Study: 6828981

Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin gluceptate
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole with tobramycin
Number of subjects: 123
Study: 28799984

Group type: EXPERIMENTAL
Intervention: Lidocaine spray (60 mg, Xylocaine 10% pump spray)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo spray (chlorhexidine gluconate 0.5% in 70% alcohol base)
Number of subjects: 17
Study: 27609658

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 25882396

Group type: EXPERIMENTAL
Intervention: Chlorambucil plus ofatumumab
Number of subjects: 447

Group type: COMPARATOR
Intervention: Chlorambucil alone
Number of subjects: 447
Study: 23078405

Group type: EXPERIMENTAL
Intervention: Play activities
Number of subjects: 53

Group type: COMPARATOR
Intervention: No play activities (Control)
Number of subjects: 53
Study: 21699717

Group type: EXPERIMENTAL
Intervention: Self-regulation intervention delivered by practice nurses and healthcare assistants, consisting of behaviour change techniques designed to increase walking self-efficacy and help translate intentions into behaviour change.
Number of subjects: 400

Group type: COMPARATOR
Intervention: Information provision control intervention, consisting of written materials promoting walking and a short unstructured discussion about increasing walking.
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 400
Study: 18706705

Group type: EXPERIMENTAL
Intervention: 40 mg rosuvastatin loading before PCI
Number of subjects: 445

Group type: COMPARATOR
Intervention: No statin treatment before PCI (Control group)
Number of subjects: 445
Study: 16564621

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 ml, 20mg/ml lidocaine and 12.5 microg/ml adrenaline)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Saline (1.5 ml, 9 mg/ml NaCl solution) (placebo)
Number of subjects: 35
Study: 12971708

Group type: EXPERIMENTAL
Intervention: Intensive group exercise programme under the supervision of a physiotherapist for six weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Home physiotherapy programme (control group)
Number of subjects: 51
Study: 11117586

Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (solid meal ingestion)
Number of subjects: 0
Study: 9206239

Group type: EXPERIMENTAL
Intervention: Wenxin decoction
Number of subjects: 122

Group type: COMPARATOR
Intervention: Isosorbide dinitrate
Number of subjects: 122
Study: 1419014

Group type: EXPERIMENTAL
Intervention: Aerosolized lidocaine followed by IV lidocaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aerosolized placebo followed by IV lidocaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aerosolized lidocaine followed by IV placebo
Number of subjects: 40

Group type: COMPARATOR
Intervention: Aerosolized placebo followed by IV placebo
Number of subjects: 40
Study: 6537916

Group type: EXPERIMENTAL
Intervention: Empiric antibiotic treatment for fever
Number of subjects: 55
Study: 30802277

Group type: EXPERIMENTAL
Intervention: Enhanced HIV prevention counseling (ERHTEC) every 3 months throughout follow‐up.
Number of subjects: 820

Group type: COMPARATOR
Intervention: Standard counseling at the time of HIV retesting.
Number of subjects: 820
Study: 30105362

Group type: EXPERIMENTAL
Intervention: Fludrocortisone (0.1 to 0.4 mg per day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline only
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Number of subjects: 36
Study: 27438627

Group type: EXPERIMENTAL
Intervention: ONS solution 2 hours before surgery
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (fasting)
Number of subjects: 24
Study: 25440377

Group type: EXPERIMENTAL
Intervention: 15g/day of E. angustifolia L. medulla for 8 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 15g/day of E. angustifolia L. whole fruit for 8 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 90
Study: 23128099

Group type: EXPERIMENTAL
Intervention: Protein meal
Number of subjects: 14

Group type: COMPARATOR
Intervention: Low-calorie yoghurt (control)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Other test meals (rolled oats, sugar, cornflakes, walnuts)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Test meals (including protein, rolled oats, sugar, cornflakes, walnuts)
Number of subjects: 14
Study: 20946926

Group type: EXPERIMENTAL
Intervention: High caloric food pictures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low caloric food pictures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peripheral measures
Number of subjects: 0
Study: 18056193

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2 i.v. infusion over 1 hour)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Single-nucleotide polymorphisms (SNPs) in CAR, HNF4alpha, and PXR
Number of subjects: 101
Study: 15957134

Group type: EXPERIMENTAL
Intervention: Immediate-Treatment Group (ITG)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Deferred-Treatment Group (DTG)
Number of subjects: 56